Supplemental Table 6.
Univariable analyses of association between trial features and results reporting within 3 years of completion
| Trail feature | Odds ratio (95% confidence interval) | P value |
|---|---|---|
| Fundinga | ||
| Industry | Reference | |
| Academic | 0.48 (0.27–0.82) | .008 |
| United States government | 0.93 (0.47–1.83) | .83 |
| Primary purpose | ||
| Treatment | Reference | |
| Basic science | 0.86 (0.33–2.26) | .76 |
| Prevention | 0.71 (0.48–1.07) | .10 |
| Otherb | 0.71 (0.44–1.14) | .15 |
| Phase | ||
| Phase 2/3–3 | Reference | |
| Not Applicablec | 0.68 (0.40–1.16) | .16 |
| Phase 1 | 0.81 (0.29–2.30) | .70 |
| Phase 1/2–2 | 1.42 (0.70–2.86) | .33 |
| Phase 4 | 1.23 (0.65–2.32) | .52 |
| Enrollmentd | ||
| 100–499 | Reference | |
| 10–49 | 1.13 (0.71–1.78) | .61 |
| 50–99 | 0.87 (0.54–1.38) | .55 |
| 500–999 | 0.70 (0.31–1.59) | .40 |
| >999 | 0.44 (0.21–0.95) | .035 |
| Year | ||
| 2007–2013 | Reference | |
| 2014–2020 | 1.22 (0.85–1.73) | .28 |
| Blinding | ||
| None | Reference | |
| Double | 1.30 (0.85–2.00) | .22 |
| Single | 1.22 (0.80–1.86) | .36 |
| Randomization | ||
| Nonrandomized | Reference | |
| Randomized | 1.44 (0.87–2.38) | .16 |
| Oversight by a data safety monitoring committee | ||
| No | Reference | |
| Yes | 1.23 (0.87–1.74) | .25 |
| Location | ||
| Low- and middle-income countries only | Reference | |
| High-income countries | 2.04 (1.34–3.13) | <.001 |
| Number of facilities | ||
| 1 | Reference | |
| >2 | 1.74 (1.18–2.56) | .005 |
| Therapeutic focuse | ||
| All other therapeutic foci | Reference | |
| Cesarean delivery | 1.55 (1.01–2.37) | .043 |
| Nutrition | 0.56 (0.31–0.99) | .046 |
| Anesthesia | 1.52 (0.95–2.42) | .08 |
| Infection | 1.12 (0.67–1.87) | .67 |
| Fetal | 1.16 (0.63–2.13) | .63 |
| Mental health | 1.01 (0.53–1.95) | .97 |
| Early delivery | 0.87 (0.39–1.94) | .74 |
| Diabetes mellitus | 0.75 (0.35–1.58) | .45 |
Steinberg et al. The obstetrical clinical trial landscape. AJOG MFM 2021.
Funding categories were determined with data on the sponsor and collaborators. Industry funding includes trials with an industry sponsor or collaborating agency United States government trials include remaining trials with a United States government sponsor or collaborating agency
Other primary purposes include diagnostic, screening, supportive care, health services research, and other
On ClinicalTrials.gov, “Not Applicable” is used to describe trials without Food and Drug Administration–defined phases, including trials of devices or behavioral interventions
Enrollment included both actual enrollment (for completed trials) and anticipated enrollment (for ongoing trials with continued enrollment)
Trials could have >1 therapeutic focus. For analysis, each therapeutic focus was treated as a binary variable.